Johnson & Johnson (JNJ.US) shares are gaining 4% during today's session, after the drug and healthcare products manufacturer reported second-quarter results that exceeded analysts' expectations. On the other hand, the company lowered its adjusted earnings per share forecast for the full year due to costs associated with mergers and acquisitions resulting from recent transactions. However, it seems that in the eyes of investors, higher costs incurred now will be offset by higher profits in the future.
ANNUAL FORECAST
- Expected adjusted earnings per share (EPS) $9.97 to $10.07, previously $10.57 to $10.72
- Expected adjusted operating EPS $10 to $10.10, previously $10.60 to $10.75
- Expected revenues between $88 billion to $88.4 billion (unchanged)
SECOND QUARTER RESULTS
- Adjusted EPS $2.82, estimated $2.71
- Revenues $22.45 billion, estimated $22.32 billion
- MedTech revenues $7.96 billion, estimated $8.22 billion
- Pharmaceutical division revenues $14.49 billion, estimated $14.08 billion
Source: xStation
US OPEN: Wall Street awaits FOMC minutes
DE40: DAX hits a 2.5-month high 📈 Rheinmetall jumps on renewed Russia–Ukraine tensions
Lack of momentum halts stock market gains, as silver stabilizes
US OPEN: Start of the week with mild discounts, amid geopolitical tensions
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
